Filter Results:
(422)
Show Results For
- All HBS Web
(635)
- People (4)
- News (110)
- Research (422)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(635)
- People (4)
- News (110)
- Research (422)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Sort by
- September 1990 (Revised January 1992)
- Case
Eli Lilly and Co. (A): Globalization
Examines the changes taking place in Eli Lilly in response to the globalization of the pharmaceuticals industry. Identifies the steps taken by management, problems currently faced, and challenges for the future. Allows examination of the process of implementing a... View Details
Keywords: Change; Globalization; Global Strategy; Business or Company Management; Problems and Challenges; Perspective; Pharmaceutical Industry
Yoshino, Michael Y. "Eli Lilly and Co. (A): Globalization." Harvard Business School Case 391-032, September 1990. (Revised January 1992.)
- 23 Mar 2003
- Research & Ideas
AIDS in Africa—What’s the Solution?
according to panelists from the healthcare field and the pharmaceutical industry, is delivering drugs that are donated or available at reduced prices to patients who need them. Government Priorities Dr. Konji Sebati, a physician with the... View Details
Keywords: by Julie Jette
- Article
Managing Alliances with the Balanced Scorecard
By: Robert S. Kaplan, David P. Norton and Bjarne Rugelsjoen
The article addresses failures in strategic alliances and illustrates, via a detailed description of the successful strategic alliance between Solvay Pharmaceuticals Inc. and Quintiles company how the creation of a strategy map and Balanced Scorecard helps align the... View Details
Keywords: Alliances; Balanced Scorecard; Employees; Alignment; Corporate Governance; Interests; Management Practices and Processes; Goals and Objectives; Partners and Partnerships
Kaplan, Robert S., David P. Norton, and Bjarne Rugelsjoen. "Managing Alliances with the Balanced Scorecard." Harvard Business Review 88, nos. 1/2 (January–February 2010): 114–120.
- October 2000 (Revised June 2017)
- Case
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
In 2016, the new CEO of Vyaderm Pharmaceuticals introduces an Economic Value Added (EVA) program to focus the company on long-term shareholder value. The EVA program consists of three elements: EVA centers (business units), EVA drivers (operational practices that... View Details
Keywords: Compensation and Benefits; Employee Relationship Management; Economic Growth; Economic Systems; Management; Motivation and Incentives; Organizational Design; Organizational Structure; Performance Evaluation; Decision Choices and Conditions; Pharmaceutical Industry; Washington (state, US)
Simons, Robert, and Indra A. Reinbergs. "Vyaderm Pharmaceuticals: The EVA Decision." Harvard Business School Case 101-019, October 2000. (Revised June 2017.)
- July 2016
- Case
Product Portfolio Management at Genentech
By: Kevin Schulman and Jamie Gresh
Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details
Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Pharmaceutical Industry; United States
Schulman, Kevin, and Jamie Gresh. "Product Portfolio Management at Genentech." Harvard Business School Case 317-012, July 2016.
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Pharmaceutical Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- October 1986 (Revised August 2015)
- Case
Advanced Medical Technology Corporation
By: Thomas R. Piper and Steven Rogers
A loan officer must decide whether to lend $8 million to a rapidly growing high technology company. The company has had a series of relationships with three other banks. Reports from loan officers at these banks are mixed and raise questions as to the ease with which a... View Details
Keywords: Decision Making; Commercial Banking; Financing and Loans; Financial Condition; Technology Industry
Piper, Thomas R., and Steven Rogers. "Advanced Medical Technology Corporation." Harvard Business School Case 287-028, October 1986. (Revised August 2015.)
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details
Keywords: Governing Rules, Regulations, and Reforms; Ethics; Business and Government Relations; Communication Strategy; Health Care and Treatment; Monopoly; Intellectual Property; Research and Development; Price; Pharmaceutical Industry; London
Emmons, Willis M., III. "Burroughs Wellcome and AZT (A)." Harvard Business School Case 792-004, September 1991. (Revised February 1993.)
- 11 Sep 2007
- First Look
First Look: September 11, 2007
Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an... View Details
Keywords: Martha Lagace
- September 2013 (Revised February 2016)
- Case
GlaxoSmithKline: Sourcing Complex Professional Services
By: Heidi K. Gardner and Silvia Hodges Silverstein
Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional time-based billing with data-driven decision making and an online reverse auction. In... View Details
Keywords: Legal Industry; Procurement; Professional Service Firms; Pricing; Competition; Change Management; Supply Chain Management; Legal Liability; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry
Gardner, Heidi K., and Silvia Hodges Silverstein. "GlaxoSmithKline: Sourcing Complex Professional Services." Harvard Business School Case 414-003, September 2013. (Revised February 2016.)
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Bowen, H. Kent, and Courtney Purrington. "Novartis AG: Science-Based Business." Harvard Business School Case 608-136, March 2008.
- March 2012
- Article
Managing Political Risk in Global Business: Beiersdorf 1914-1990
By: Geoffrey Jones and Christina Lubinski
This article is concerned with business strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks... View Details
Keywords: Business Strategy; Government and Politics; Risk Management; Brands and Branding; Problems and Challenges; Communication Technology; Cost; Trademarks; Strategy; Pharmaceutical Industry; Germany
Jones, Geoffrey, and Christina Lubinski. "Managing Political Risk in Global Business: Beiersdorf 1914-1990." Enterprise & Society 13, no. 1 (March 2012): 85–119.
- August 2011 (Revised October 2011)
- Case
PureTech Ventures in 2011
By: Andrei Hagiu, Cesar Castro and Sarah Murphy
In early May 2011, Daphne Zohar, founder and managing partner of PureTech Ventures, a life science venture creation company in Boston, MA, was reviewing a term sheet she had just received from a venture capital (VC) firm for one of PureTech's portfolio companies. The... View Details
Keywords: Business Ventures; Business Startups; Venture Capital; Investment; Innovation and Invention; Negotiation; Partners and Partnerships; Science-Based Business; Opportunities; Boston
Hagiu, Andrei, Cesar Castro, and Sarah Murphy. "PureTech Ventures in 2011." Harvard Business School Case 712-419, August 2011. (Revised October 2011.)
- May 2007 (Revised September 2008)
- Case
Biocon Limited
By: Krishna G. Palepu and Ananth Chepuri
Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details
Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India
Palepu, Krishna G., and Ananth Chepuri. "Biocon Limited." Harvard Business School Case 107-083, May 2007. (Revised September 2008.)
- October 2024 (Revised February 2025)
- Case
Lanco Medical Group: Fostering Happiness for Growth
By: Susanna Gallani, Jenyfeer Martínez Buitrago and Katherine Sonnefeldt
This case describes how Lanco Medical Group, a fast-growing pharmaceutical distributor serving Latin America, approached the design of their employee benefits and incentives program. After learning about gaps between what leadership believed motivated employees and... View Details
- 16 Jan 2018
- First Look
First Look at New Research and Ideas, January 16, 2018
companies offer a direct stake in the company's performance through stock, a share in profits, or both. Companies with employee stock ownership plans report significantly higher sales growth and higher... View Details
Keywords: Sean Silverthorne
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- September 2007 (Revised December 2008)
- Case
Michael Fernandes at Nicholas Piramal
By: Michel Anteby and Nitin Nohria
Michael Fernandes, the Director of Custom Manufacturing Operations at the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedules a meeting with three of his reports, whose interpersonal conflicts with one another are causing his business development... View Details
Keywords: Interpersonal Communication; Management Skills; Groups and Teams; Conflict Management; Cooperation; Pharmaceutical Industry; India; United Kingdom; Canada
Anteby, Michel, and Nitin Nohria. "Michael Fernandes at Nicholas Piramal." Harvard Business School Case 408-001, September 2007. (Revised December 2008.)
- March 2008 (Revised July 2011)
- Supplement
Cadbury Schweppes: Capturing Confectionery (D)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (D)." Harvard Business School Supplement 708-491, March 2008. (Revised July 2011.)